Key clinical point: All patients with a Candida bloodstream infection should receive an infectious disease consultation.
Major finding: Patients who received an ID consult for a Candida bloodstream infection had a significantly lower 90-day mortality rate than did those who did not (29% vs. 51%).
Study details: Retrospective, single-center cohort study of 1,691 patients 18 years or older with Candida bloodstream infection from 2002 to 2015.
Disclosures: The study was funded by the Astellas Global Development Pharma, the Washington University Institute of Clinical and Translational Sciences, and the Agency for Healthcare Research and Quality. Several of the authors had financial connections to Astellas Global Development or other pharmaceutical companies.
Mejia-Chew C et al. Lancet Infect Dis. 2019;19:1336-44.